Georgia Bio Statement on BD Sterilization Plant In Georgia

Closure May Lead to Medical Device Shortage & Impact Patients

October 25, 2019 06:06 PM Eastern Daylight Time

ATLANTA–( BUSINESS WIRE )–Georgia Bio member companies are dedicated to improving patients’ lives-enhancing patient safety and expanding patient access to innovative treatments. Public health and environmental protection are central to the values of the life sciences community. Our member companies continually strive to exceed regulations and reduce their environmental footprint.

We are very concerned with the potential shut down of BD’s Covington facility over the use of EtO. Ethylene oxide is the safest, and sometimes, only method for ensuring the sterilization of medical devices for clinicians and patients. Approximately 50% of all medical devices are sterilized using EtO, accounting for more than 20 billion devices annually in the U.S. Many of our members manufacture devices and products that cannot be sterilized by any other means due to their complex nature, including pacemakers, implantable defibrillators, cardiac catheters, biopsy instruments and surgical fixation devices and vascular access devices including PICCs, midlines and ports. BD is the largest supplier of urinary catheters that are used in almost every surgical procedure that takes longer than 2 hours. They are also one of the only suppliers for pediatric vascular access devices used to deliver chemotherapy to children with cancer.

Georgia Bio believes policy makers have an obligation to protect the public from harmful emissions from any source, and we believe all industrial facilities in our state should meet or exceed safety standards. We support an open and transparent debate regarding EtO that is grounded in scientific fact, but caution that a hasty decision to close this facility or severely restrict the use of ethylene oxide would endanger the health of thousands, possibly even millions, of patients who are relying on sterile medical products.

About Georgia Bio

Georgia Bio is an independent, non-profit 501(c)(3) trade association whose mission is to advance the growth of Georgia’s life sciences industry and foster strategic partnerships that can create a healthier world. Georgia Bio member companies are dedicated to improving patients’ lives – enhancing patient safety and expanding patient access to innovative treatments. Public health and environmental protection are central to the values of the life sciences community. Georgia Bio members include bioscience and medtech companies, academic and research institutions, life science service providers, digital health companies, and related organizations. For more information, visit  www.gabio.org  or follow us on  Twitter @Georgia_Bio.

Contacts

Joseph Santoro 
404-334-7538 
jsantoro@gabio.org

January 20, 2026
January 20, 2026. Paulding County has been designated a BioReady Silver Community by Georgia Life Sciences, the state’s leading life sciences membership organization. The BioReady designation recognizes communities that demonstrate strong zoning practices, infrastructure capacity, and readiness to support biotechnology and life sciences development. “We are proud to recognize Paulding County as our newest BioReady Silver community,” said Maria Thacker-Goethe, President and CEO of Georgia Life Sciences. “Paulding County’s proactive planning, growing workforce, and access to regional healthcare and transportation infrastructure position it well to support life sciences manufacturing and commercialization. Through the BioReady program, we champion communities that are intentionally preparing to compete for industry investment and job growth.” Paulding County’s designation reflects its commitment to thoughtful land-use planning, scalable infrastructure, and business-friendly development policies that support life sciences and advanced manufacturing uses. Located in the northwest Atlanta metro region, the county offers access to a strong labor pool, major transportation corridors, and regional healthcare systems, making it an attractive option for biotechnology, medical device, diagnostics, and related life sciences companies seeking room to grow. “Georgia BioReady designation validates Paulding County’s readiness to support bioscience investment and strengthens our position as a growing hub for advanced industries,” said Alex Almodovar, President & CEO, Paulding County Economic Development Inc. & Industrial Building Authority The BioReady rating system evaluates communities across three tiers—Bronze, Silver, and Gold—based on their readiness to attract and support life sciences facilities. Through these ratings, Georgia Life Sciences helps municipalities better showcase biotech-appropriate sites, strengthen infrastructure planning, and clearly identify life sciences-friendly locations. This approach enables communities like Paulding County to compete more effectively for private investment and high-quality job creation. Georgia Life Sciences advances innovation, strengthens the workforce pipeline, and grows Georgia’s life sciences economy through the BioReady Community program, modeled after MassBio’s nationally recognized rating system, which assesses a community’s readiness to host life sciences facilities based on zoning practices and infrastructure capacity. About Georgia Life Sciences Georgia Life Sciences, founded in 1989, is a non-profit, membership-based organization that promotes the interests and growth of the life sciences industry. It is the state’s largest and most influential life sciences advocacy and business leadership organization working to improve access to innovative discoveries that have lifesaving impact. The association connects business, academia, government, and other allied entities involved in the application of life sciences products to fuel growth and collaboration through policy development, community programs, national industry initiatives, and a portfolio of educational and networking events. Learn more at galifesciences.org.
January 14, 2026
What happens when students see real work before choosing a future 
January 8, 2026
By: Patrick Plues | RealClearHealth January 8, 2026 For decades, America has led the global biotech industry – thanks, in part, to state-level policies that encourage research and manufacturing investments. But other countries, including China, are sparing no expense in the bid to overtake us. Beijing has officially made biotechnology a national strategic priority and is pouring billions into state-backed research and manufacturing efforts. All states should consider impactful biotech policies that grow and strengthen our domestic biotechnology industry. If states fail to utilize and replicate what are considered to be the best and most successful policies in biotech-focused economic development, the United States will soon lose its long-term leadership in developing medicines and medical technologies, which underpin our health, our economy, and our national security. Thankfully, many governors and state legislatures around the country are already answering this call -- as our new study, The U.S. Bioscience Industry: A Powerful Engine for State Economies, demonstrates. Keep Reading at https://www.realclearhealth.com/2026/01/08/americas_biotech_leadership_depends_on_the_states_1157584.html
MORE POSTS